Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. reports recurring developments in advanced genomics for precision oncology, with emphasis on personalized cancer testing, minimal residual disease monitoring and sequencing-based data analysis services. Company updates frequently center on the NeXT Personal ultrasensitive ctDNA assay, clinical test volume, clinical revenue, Medicare coverage for breast and lung cancer surveillance, and the shift toward commercial adoption of MRD testing.
News also covers clinical data presentations and publications in oncology settings, including breast, lung and colorectal cancer, as well as product features such as Real-Time Variant Tracker for therapy-resistance monitoring. Other recurring items include quarterly results, financial guidance, biopharma research applications and governance or management changes tied to the company’s precision oncology strategy.
Personalis, Inc. (Nasdaq: PSNL) announces its participation in the Digital World CB & CDx meeting from September 29 to October 1, 2020. The company will present on the ImmunoID NeXT™ platform, addressing challenges in immuno-oncology research. Dr. Kedar Hastak will highlight the platform’s ability to consolidate biomarker assays for a comprehensive view of tumor-immune interactions. Additionally, Personalis is advancing precision medicine with its NeXT Dx™ and NeXT CDx™ diagnostic initiatives. The company focuses on delivering extensive molecular data to support cancer treatment.